Immunological barriers to immunotherapy in primary and metastatic breast cancer
Patients with breast cancer obtain limited clinical benefits from immune checkpoint inhibitors (ICIs), pointing to the existence of multiple immunological alterations that cannot be simultaneously normalized with immunotherapy. Accumulating preclinical evidence suggests that radiation therapy (RT) c...
Main Authors: | Mara De Martino, Claire Vanpouille‐Box, Lorenzo Galluzzi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-08-01
|
Series: | EMBO Molecular Medicine |
Subjects: | |
Online Access: | https://doi.org/10.15252/emmm.202114393 |
Similar Items
-
LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells
by: Takahiro Yamazaki, et al.
Published: (2021-01-01) -
Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents
by: Giulia Petroni, et al.
Published: (2021-01-01) -
Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma
by: Karishma R. Rajani, et al.
Published: (2019-02-01) -
Immune Checkpoint in Glioblastoma: Promising and Challenging
by: Jing Huang, et al.
Published: (2017-05-01) -
Recent Advances in Immunotherapy in Metastatic NSCLC.
by: Pranshu Bansal, et al.
Published: (2016-11-01)